Surveillance Among Healthcare Workers for SARS-Coronavirus-2 Infection
1 other identifier
observational
512
1 country
1
Brief Summary
This study aims to investigate the epidemiology of SARS-CoV-2 infection among: i) HCW who triage patients with suspected SARS-CoV-2 infection and provide care to COVID-19 patients; and ii) laboratory personnel who test clinical samples for SARS-CoV-2 infection. After the second wave of the pandemic enrolment will be widen to any person working at the study hospitals.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Apr 2020
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 22, 2020
CompletedFirst Submitted
Initial submission to the registry
January 2, 2022
CompletedFirst Posted
Study publicly available on registry
January 4, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 30, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
April 30, 2022
CompletedMay 28, 2024
May 1, 2024
2 years
January 2, 2022
May 23, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
To determine the prevalence of symptomatic and asymptomatic SARS-CoV-2 infections among HCW.
To determine the prevalence of symptomatic and asymptomatic PCR-confirmed SARS-CoV-2 infections among HCW using a systematic sampling strategy, coupled with investigation when clinically indicated.
2020
Secondary Outcomes (7)
To define the duration of viral "shedding".
2020
To do sero-epidemiology assessment.
2022
To analyse immune responses to SARS-CoV-2 infection.
2022
To investigate the possibility of viral re-infection in this population during the study period.
2022
To establish if common cold coronaviruses (CCCV) immunity confers protection against SARS-CoV-2 infection or disease severity
2022
- +2 more secondary outcomes
Study Arms (5)
High Risk
Nurses (auxiliary nurses, enrolled nurses and professional nurses), medical doctors (interns, medical officers, registrars and consultants) and auxiliary/para-medical staff involved in the care of patients admitted for respiratory illnesses at Chris Hani Baragwanath Academic Hospital (CHBAH). This will include staff that have been assigned to work in: Internal Medicine: Staff working in the Ambulatory and Emergency Department, staff in the "pneumonia-admission" ward (ward 24), and staff in the COVID-19 confirmed case wards. Paediatrics: Staff involved in-hospital care of patients admitted to the dedicated "pneumonia ward" and COVID-19 cases wards. Intensive Care Unit: All medical staff working in the intensive care unit.
Low Risk
Nursing and medical-doctor staff that are working in the neonatal high-care and intensive care unit; who are likely to be at lower risk from SARS-CoV-2 acquisition in the health-care facility compared to their peers listed in Group 1.
Intermediate Risk
A third group, with a likely intermediate risk for hospital-facility based SARS-CoV-2 infection, are: VIDA staff involved in sample collection related to COVID-19, and laboratory personnel that will be involved in sample collection at VIDA. Nurses and medical doctors from the Obstetrics \& Gynaecology.
Mixed Risk
In 2021 with an eminent 3rd wave spreading across the country an additional group will be included comprising of any person working at CHBAH even if not in direct contact with patients.
TND group
Any person working at CHBAH or Charlotte Maxeke Johannesburg Academic Hospital (CMJAH) and Helen Joseph Hospital (HJH) even if not in direct contact with patients.
Eligibility Criteria
Any HCWs of any staff category at the study hospitals
You may qualify if:
- HCWs of any staff category at the study hospitals.
You may not qualify if:
- None
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Farzanah Laherlead
Study Sites (1)
Chris Hani Baragwanath Academic Hospital
Johannesburg, GP, 2192, South Africa
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Dr
Study Record Dates
First Submitted
January 2, 2022
First Posted
January 4, 2022
Study Start
April 22, 2020
Primary Completion
April 30, 2022
Study Completion
April 30, 2022
Last Updated
May 28, 2024
Record last verified: 2024-05